Monograph
C09CA02 - Eprosartan |
Not porphyrinogenic |
NP |
Rationale
Poorly absorbed, not metabolised.
Chemical description
Angiotensin II receptor antagonist. Weak inhibitor of CYP 2C9 in vitro. Biovailability only 13 % dependent on poor absorbtion. Excreted in unchanged form.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Teveten · Teveten 400, filmomhulde tabletten 400 mg · Teveten 600, filmomhulde tabletten 600 mgBelgium
Teveten · Teveten 600 mg compr. pellic.United Kingdom
Eprosartan · Eprosartan 300mg tablets · Eprosartan 300mg/5ml oral solution · Eprosartan 300mg/5ml oral suspension · Eprosartan 400mg tablets · Eprosartan 600mg tablets · Teveten · Teveten 300mg tablets · Teveten 400mg tablets · Teveten 600mg tabletsNorway
TevetenPoland
TevetenLuxembourg
TEVETENFinland
TevetenLatvia
Teveten
© NAPOS 2024